MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 330153 | Name: Myo-Inositol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Myo-Inositol or simply inositol, is a carbocyclic sugar that is abundant in brain and other mammalian tissues, mediates cell signal transduction in response to a variety of hormones, neurotransmitters and growth factors and participates in osmoregulation It is a sugar alcohol with half the sweetness of sucrose (table sugar). It is made naturally in human beings from glucose. Each kidney makes 2g a day; so 4g a day total is made. Other tissues synthesize it too, and the highest concentration is in the brain where it plays an important role making other neurotransmitters, and some steroid hormones bind to their receptors.

Chemical Structure

Myo-Inositol
Myo-Inositol
CAS#87-89-8

Theoretical Analysis

MedKoo Cat#: 330153

Name: Myo-Inositol

CAS#: 87-89-8

Chemical Formula: C6H12C6

Exact Mass: 180.0634

Molecular Weight: 180.16

Elemental Analysis:

Price and Availability

Size Price Availability Quantity
100g USD 250.00 2 weeks
250g USD 350.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Myo-Inositol; Hexahydroxycyclohexane; Myoinositol; NSC 8101; Nucite; Phaseomannite; Phaseomannitol; Scyllite;
IUPAC/Chemical Name
(1R,2r,3S,4R,5s,6S)-cyclohexane-1,2,3,4,5,6-hexaol
InChi Key
CDAISMWEOUEBRE-GPIVLXJGSA-N
InChi Code
InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-
SMILES Code
[C@@H]1([C@@H]([C@H]([C@@H]([C@H]([C@H]1O)O)O)O)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
i-Inositol is a chemical compound, associated lipids are found in many foods, in particular fruit, especially cantaloupe and oranges.
In vitro activity:
Under 200 μM MI (myo-inositol), algal cells exhibited 62.11% and 34.67% increases in astaxanthin and lipid content, respectively, compared to the control. The carotenogenesis and lipogenesis genes were upregulated by induction of MI. Interestingly, MI addition elevated the ethylene (ETH) content and activated antioxidant enzyme-associated gene levels, which could be involved in alleviating oxidative stress. Further data showed that the ETH signal played a positive function in stimulating astaxanthin biosynthesis under MI induction. Reference: Bioresour Technol. 2022 Dec;366:128222. https://pubmed.ncbi.nlm.nih.gov/36328171/
In vivo activity:
In order to evaluate the role of myo-inositol in cisplatin-induced injury in vivo, daily intraperitoneal injection of myo-inositol was administered to C57BL/6J mice. Severe proximal renal tubular damage (characterized by tubular dilatation, cast formation, interstitial edema, cellular vacuolization, and focal nuclear drop out) was observed in kidneys of cisplatin-treated mice, as compared with the controls (Figure 2B,E vs. Figure 2A,D). These morphologic aberrations were mitigated with the treatment of myo-inositol (Figure 2I,L vs. Figure 2H,K). The qRT-PCR analysis indicated a marked increase in KIM-1 and NGAL mRNA levels in cisplatin-treated kidneys, which were normalized with the supplementation of myo-inositol (Figure 2O,P). Taken together, these data suggest that the myo-inositol treatment ameliorates cisplatin-induced AKI. Reference: Cells. 2022 Dec 21;12(1):16. https://pubmed.ncbi.nlm.nih.gov/36611810/
Solvent mg/mL mM
Solubility
DMSO 8.0 44.41
Water 49.3 273.37
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 180.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Li Q, Zhang X, Zhao Y, Gao H, Li L, Zhang Y, Yu X. Myo-inositol facilitates astaxanthin and lipid coproduction in Haematococcus pluvialis by regulating oxidative stress and ethylene signalling. Bioresour Technol. 2022 Dec;366:128222. doi: 10.1016/j.biortech.2022.128222. Epub 2022 Nov 1. PMID: 36328171. 2. Watkins OC, Cracknell-Hazra VKB, Pillai RA, Selvam P, Yong HEJ, Sharma N, Patmanathan SN, Cazenave-Gassiot A, Bendt AK, Godfrey KM, Lewis RM, Wenk MR, Chan SY. Myo-Inositol Moderates Glucose-Induced Effects on Human Placental 13C-Arachidonic Acid Metabolism. Nutrients. 2022 Sep 26;14(19):3988. doi: 10.3390/nu14193988. PMID: 36235641; PMCID: PMC9572372. 3. Qi H, Deng F, Wang Y, Zhang H, Kanwar YS, Dai Y. Myo-Inositol Supplementation Alleviates Cisplatin-Induced Acute Kidney Injury via Inhibition of Ferroptosis. Cells. 2022 Dec 21;12(1):16. doi: 10.3390/cells12010016. PMID: 36611810; PMCID: PMC9818458. 4. Ebert T, Heinz DE, Almeida-Corrêa S, Cruz R, Dethloff F, Stark T, Bajaj T, Maurel OM, Ribeiro FM, Calcagnini S, Hafner K, Gassen NC, Turck CW, Boulat B, Czisch M, Wotjak CT. Myo-Inositol Levels in the Dorsal Hippocampus Serve as Glial Prognostic Marker of Mild Cognitive Impairment in Mice. Front Aging Neurosci. 2021 Nov 12;13:731603. doi: 10.3389/fnagi.2021.731603. PMID: 34867270; PMCID: PMC8633395.
In vitro protocol:
1. Li Q, Zhang X, Zhao Y, Gao H, Li L, Zhang Y, Yu X. Myo-inositol facilitates astaxanthin and lipid coproduction in Haematococcus pluvialis by regulating oxidative stress and ethylene signalling. Bioresour Technol. 2022 Dec;366:128222. doi: 10.1016/j.biortech.2022.128222. Epub 2022 Nov 1. PMID: 36328171. 2. Watkins OC, Cracknell-Hazra VKB, Pillai RA, Selvam P, Yong HEJ, Sharma N, Patmanathan SN, Cazenave-Gassiot A, Bendt AK, Godfrey KM, Lewis RM, Wenk MR, Chan SY. Myo-Inositol Moderates Glucose-Induced Effects on Human Placental 13C-Arachidonic Acid Metabolism. Nutrients. 2022 Sep 26;14(19):3988. doi: 10.3390/nu14193988. PMID: 36235641; PMCID: PMC9572372.
In vivo protocol:
1. Qi H, Deng F, Wang Y, Zhang H, Kanwar YS, Dai Y. Myo-Inositol Supplementation Alleviates Cisplatin-Induced Acute Kidney Injury via Inhibition of Ferroptosis. Cells. 2022 Dec 21;12(1):16. doi: 10.3390/cells12010016. PMID: 36611810; PMCID: PMC9818458. 2. Ebert T, Heinz DE, Almeida-Corrêa S, Cruz R, Dethloff F, Stark T, Bajaj T, Maurel OM, Ribeiro FM, Calcagnini S, Hafner K, Gassen NC, Turck CW, Boulat B, Czisch M, Wotjak CT. Myo-Inositol Levels in the Dorsal Hippocampus Serve as Glial Prognostic Marker of Mild Cognitive Impairment in Mice. Front Aging Neurosci. 2021 Nov 12;13:731603. doi: 10.3389/fnagi.2021.731603. PMID: 34867270; PMCID: PMC8633395.
1: Mutlu N, Kumar A. Messengers for morphogenesis: inositol polyphosphate signaling and yeast pseudohyphal growth. Curr Genet. 2018 Aug 12. doi: 10.1007/s00294-018-0874-0. [Epub ahead of print] Review. PubMed PMID: 30101372. 2: Eid AH, El-Yazbi AF, Zouein F, Arredouani A, Ouhtit A, Rahman MM, Zayed H, Pintus G, Abou-Saleh H. Inositol 1,4,5-Trisphosphate Receptors in Hypertension. Front Physiol. 2018 Jul 26;9:1018. doi: 10.3389/fphys.2018.01018. eCollection 2018. Review. PubMed PMID: 30093868; PubMed Central PMCID: PMC6071574. 3: Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D'Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018 Aug 4. doi: 10.1007/s00404-018-4861-y. [Epub ahead of print] Review. PubMed PMID: 30078122. 4: Uličná L, Paprčková D, Fáberová V, Hozák P. Phospholipids and inositol phosphates linked to the epigenome. Histochem Cell Biol. 2018 Sep;150(3):245-253. doi: 10.1007/s00418-018-1690-9. Epub 2018 Jul 7. Review. PubMed PMID: 29982846. 5: Tabrizi R, Ostadmohammadi V, Lankarani KB, Peymani P, Akbari M, Kolahdooz F, Asemi Z. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018 May 24;17(1):123. doi: 10.1186/s12944-018-0779-4. Review. PubMed PMID: 29793496; PubMed Central PMCID: PMC5968598. 6: Uchida K, Nakazawa M, Yamagishi C, Mikoshiba K, Yamagishi H. Inositol Trisphosphate Receptors in the Vascular Development. 2016 Jun 25. In: Nakanishi T, Markwald RR, Baldwin HS, Keller BB, Srivastava D, Yamagishi H, editors. Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function and Cellular Interaction to Morphology [Internet]. Tokyo: Springer; 2016. Chapter 32. Available from http://www.ncbi.nlm.nih.gov/books/NBK500313/ PubMed PMID: 29787154. 7: Guo X, Guo S, Miao Z, Li Z, Zhang H. Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. J Diabetes Complications. 2018 Mar;32(3):342-348. doi: 10.1016/j.jdiacomp.2017.07.007. Epub 2017 Jul 21. Review. PubMed PMID: 29325728. 8: Ando H, Kawaai K, Bonneau B, Mikoshiba K. Remodeling of Ca(2+) signaling in cancer: Regulation of inositol 1,4,5-trisphosphate receptors through oncogenes and tumor suppressors. Adv Biol Regul. 2018 May;68:64-76. doi: 10.1016/j.jbior.2017.12.001. Epub 2017 Dec 20. Review. PubMed PMID: 29287955. 9: Egorova PA, Bezprozvanny IB. Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders. FEBS J. 2017 Dec 18. doi: 10.1111/febs.14366. [Epub ahead of print] Review. PubMed PMID: 29253316. 10: Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, Sun Y. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017 Dec;96(49):e8842. doi: 10.1097/MD.0000000000008842. Review. PubMed PMID: 29245250; PubMed Central PMCID: PMC5728865. 11: Wickner RB, Edskes HK, Bezsonov EE, Son M, Ducatez M. Prion propagation and inositol polyphosphates. Curr Genet. 2018 Jun;64(3):571-574. doi: 10.1007/s00294-017-0788-2. Epub 2017 Dec 14. Review. PubMed PMID: 29243174; PubMed Central PMCID: PMC5949079. 12: Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11:CD003053. doi: 10.1002/14651858.CD003053.pub6. Review. PubMed PMID: 29183107. 13: Dinicola S, Minini M, Unfer V, Verna R, Cucina A, Bizzarri M. Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders. Int J Mol Sci. 2017 Oct 20;18(10). pii: E2187. doi: 10.3390/ijms18102187. Review. PubMed PMID: 29053604; PubMed Central PMCID: PMC5666868. 14: Scioscia M. D-chiro inositol phosphoglycans in preeclampsia: Where are we, where are we going? J Reprod Immunol. 2017 Nov;124:1-7. doi: 10.1016/j.jri.2017.09.010. Epub 2017 Sep 28. Review. PubMed PMID: 28982033. 15: Saiardi A, Azevedo C, Desfougères Y, Portela-Torres P, Wilson MSC. Microbial inositol polyphosphate metabolic pathway as drug development target. Adv Biol Regul. 2018 Jan;67:74-83. doi: 10.1016/j.jbior.2017.09.007. Epub 2017 Sep 22. Review. PubMed PMID: 28964726. 16: Jung JY, Ried MK, Hothorn M, Poirier Y. Control of plant phosphate homeostasis by inositol pyrophosphates and the SPX domain. Curr Opin Biotechnol. 2018 Feb;49:156-162. doi: 10.1016/j.copbio.2017.08.012. Epub 2017 Sep 8. Review. PubMed PMID: 28889038. 17: Mendoza N, Pérez L, Simoncini T, Genazzani A. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017 Nov;35(5):529-535. doi: 10.1016/j.rbmo.2017.07.005. Epub 2017 Jul 14. Review. PubMed PMID: 28756130. 18: Orrù B, Circo R, Logoteta P, Petousis S, Carlomagno G. Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):83-88. Review. PubMed PMID: 28724181. 19: Colone M, Calcabrini A, Unfer V, Stringaro A. Contribution of electron microscopy to study in vitro inositol effects on human spermatozoa. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):4-9. Review. PubMed PMID: 28724179. 20: Condorelli RA, La Vignera S, Mongioì LM, Vitale SG, Laganà AS, Cimino L, Calogero AE. Myo-inositol as a male fertility molecule: speed them up! Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):30-35. Review. PubMed PMID: 28724176.